mRNA Cap analog
HanmiCap® - Proprietary 5' Cap analogs for in vitro transcription
HanmiCap® 11
7-methyl-3'mesyloxy-guanosine-5'-triphosphate-5'-2'methoxy-adenosine-3'-monophosphate-uridine
HanmiCap® 20
7-methyl-3'mesyloxy-guanosine-5'-triphosphate-5'-2'methoxy-adenosine-3'-monophosphate-N1-methylpseudouridine
| HanmiC ap® 13 | Order Quantity | USD/umol | Total Price (USD) | Grade |
|---|---|---|---|---|
|
1 μmol |
Inquiry (Click) |
Inquiry (Click) |
R&D ------------- Clinical Trials |
| 5 μmol | ||||
| 10 μmol | ||||
| 50 μmol | ||||
| 100 μmol |
| HanmiC ap® 13 | Order Quantity | USD/umol | Total Price (USD) | Grade |
|---|---|---|---|---|
|
1 μmol |
Inquiry (Click) |
Inquiry (Click) |
R&D ------------- Clinical Trials |
| 5 μmol | ||||
| 10 μmol | ||||
| 50 μmol | ||||
| 100 μmol |
· HanmiCap® 11 and HanmiCap® 20 are proprietary AU Cap analogs for the in vitro transcription of self-amplifying RNA (saRNA).
· HanmiCap® IP was approved by the Korean Intellectual Property Office (Patent No. 10-2692464), and is going through international approval through PCT.
· Initial test sample provided for free (10 μmol)
· No additional running royalties
· GMP Manufacturing available
Product Performance
Protein expression (%) (HeLa cell-free system)
· HanmiCap® 11 and HanmiCap® 20 showed higher protein expression in HeLa cell-free system against the Commercial Cap AU.